Details of Disease

Disease Name

Atypical endometrial hyperplasia

endometrial hyperplasia with atypia; atypical hyperplasia of endometrium; atypical hyperplasia of the endometrium

Definition

An endometrial hyperplasia characterized by cytologic and architectural changes which may lead to endometrial carcinoma. Despite the atypical features and possible course, there is debate on whether to consider this a neoplasm. The relationship with endometrial intraepithelial neoplasia is also unclear.

Disease Hierarchy

DISK4DFB: Hyperplasia

DIS0837X: Endometrial disorder

DIS2POYG: Atypical endometrial hyperplasia

Disease Identifiers

MONDO ID

MONDO_0006096

MESH ID

D004714

UMLS CUI

C0349579

MedGen ID

138105

SNOMED CT ID

277158007

General Information of Disease (ID: DIS2POYG)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Levonorgestrel	DM1DP7T	Approved	Small molecular drug	[1]
Megesterol acetate	DMQ1Q37	Approved	NA	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CDKN1C	TTBSUAR	Strong	Biomarker	[3]
PTEN	TTXJ3W7	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARID1A	OTRWDV3P	moderate	Genetic Variation	[5]
CELSR2	OTON6JSZ	Strong	Biomarker	[6]
CSRP1	OTUS7RM2	Strong	Biomarker	[6]
DDX1	OT3U8FD0	Strong	Biomarker	[6]
NOP53	OTA2YKO6	Definitive	Altered Expression	[7]
RBL2	OTBQSOE6	Definitive	Altered Expression	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DOT(s)

References

1	Levonorgestrel FDA Label
2	Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med. 2021 Feb;112(1):55-69.
3	Cyclic changes in the expression of p57(kip2) in human endometrium and its regulation by steroid hormones in endometrial stromal cells in vitro. Reprod Sci. 2012 Jan;19(1):92-101. doi: 10.1177/1933719111414209. Epub 2011 Nov 7.
4	PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer?.APMIS. 2019 Apr;127(4):161-169. doi: 10.1111/apm.12938.
5	ARID1A gene mutation in ovarian and endometrial cancers (Review).Oncol Rep. 2016 Feb;35(2):607-13. doi: 10.3892/or.2015.4421. Epub 2015 Nov 16.
6	Hormonally active doses of isoflavone aglycones promote mammary and endometrial carcinogenesis and alter the molecular tumor environment in Donryu rats.Toxicol Sci. 2012 Mar;126(1):39-51. doi: 10.1093/toxsci/kfs016. Epub 2012 Jan 16.
7	Abnormal Expression of PICT-1 and Its Codon 389 Polymorphism Is a Risk Factor for Human Endometrial Cancer.Oncology. 2018;95(1):43-51. doi: 10.1159/000487189. Epub 2018 Apr 4.
8	Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma.Hum Pathol. 2001 Apr;32(4):360-7. doi: 10.1053/hupa.2001.23514.